Image-guided EMT inhibition for treating metastatic breast cancer

图像引导 EMT 抑制治疗转移性乳腺癌

• 批准号: 9301500
• 负责人: ZHENG-RONG LU
• 金额: $ 47.39万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-07-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9301500
• 关键词: Accounting; Actin-Binding Protein; Adverse effects; Biological; Blood Vessels; Breast Cancer Cell; Breast cancer metastasis; Carcinoma; Cells; Cessation of life; Combined Modality Therapy; Contrast Media; Data; Development; Diagnosis; Disease; Down-Regulation; Effectiveness; Epithelial; Epithelial Cells; Event; Family; Fibronectins; Goals; Image; Imaging technology; In Vitro; Injection of therapeutic agent; Integrin beta3; Lead; Life; Lipids; Magnetic Resonance Imaging; Mesenchymal; Metastatic breast cancer; Micrometastasis; Modeling; Molecular; Molecular Target; Monitor; Morphology; Multi-Drug Resistance; Mus; Neoplasm Metastasis; Outcome; Patients; Phenotype; Primary Neoplasm; Property; Proteins; RNA Interference; Recurrent disease; Regimen; Regulation; Regulator Genes; Resistance; SOX4 gene; Small Interfering RNA; System; Therapeutic; Time; Treatment Efficacy; Treatment Protocols; Tumor Tissue; United States; Woman; cancer cell; cancer imaging; cancer subtypes; chemotherapy; clinical development; contrast enhanced; effective therapy; image guided; improved; in vivo; innovation; malignant breast neoplasm; member; molecular imaging; nanoparticle; non-invasive imaging; novel therapeutics; preclinical development; premature; prevent; public health relevance; response; stem; targeted delivery; targeted imaging; targeted treatment; therapeutic siRNA; therapeutic target; therapy outcome; triple-negative invasive breast carcinoma; tumor

 DESCRIPTION (provided by applicant): The goal of this project is to develop innovative image-guided EMT inhibition by targeting the proteins in the key biological event associated with metastasis using RNAi to effectively treat metastatic BC. Metastatic breast cancer is the leading cause of the premature deaths of women diagnosed with the disease in the United States. Currently, there are limited treatment options for the patients whose breast cancer becomes multidrug resistance and relapsed disease. Epithelial-mesenchymal transition (EMT) is a key biological event associated with breast cancer metastasis and multidrug resistance. We have identified several markers of breast cancer EMT for imaging metastatic breast cancer and for effective treatment of metastatic breast cancer by inhibiting cancer cell EMT and resensitizing the cells to chemotherapy under imaging guidance. In this project, we will develop molecular MRI and DCE-MRI to direct the inhibition of BC EMT using targeted lipid siRNA nanoparticles in treating metastatic BC. We will develop targeted multifunctional lipid siRNA delivery systems to down-regulate the expression of key proteins that promote cancer cell EMT for effective inhibition of BC EMT and treatment of metastatic BC alone and in combination with chemotherapy under imaging guidance. Non-invasive and timely assessment of therapeutic efficacy of the new therapeutic regimens using the imaging technologies will guide the optimization of the delivery systems and treatment protocols to achieve the best possible outcomes and to cure the disease. The specific aims of this project are 1) to first establish molecular imaging technologies for non-invasive image-guided inhibition of EMT with targeted multifunctional siRNA delivery systems in treating metastatic breast cancer; 2) to evaluate and optimize image-guided silence of EMT-regulatory genes and inhibition of BC EMT and metastasis using targeted multifunctional siRNA delivery systems; 3) to evaluate and optimize image-guided combination therapy of the multifunctional siRNA delivery systems and chemotherapeutics in treating TNBC. Substantial preliminary data have been obtained to demonstrate the effectiveness of the proposed image-guided therapeutic regimens in treating metastatic breast cancer. Our long-term goal is to develop an image-guided therapeutic approach to effectively treat life-threatening metastatic BC.

 描述（由申请人提供）：该项目的目标是通过使用RNAi靶向与转移相关的关键生物事件中的蛋白质来开发创新的图像引导的EMT抑制，以有效治疗转移性BC。在美国，转移性乳腺癌是被诊断患有该疾病的妇女过早死亡的主要原因。目前，对于乳腺癌成为多药耐药和复发性疾病的患者，治疗选择有限。上皮-间质转化（EMT）是与乳腺癌转移和多药耐药相关的关键生物学事件。我们已经确定了乳腺癌EMT的几个标志物成像转移性乳腺癌和转移性乳腺癌的有效治疗，通过抑制癌细胞EMT和再敏感的细胞化疗成像指导下。在本项目中，我们将开发分子MRI和DCE-MRI，以指导使用靶向脂质siRNA纳米颗粒治疗转移性BC来抑制BC EMT。我们将开发靶向多功能脂质siRNA递送系统，以下调促进癌细胞EMT的关键蛋白的表达，从而有效抑制BC EMT并单独治疗转移性BC以及在成像引导下与化疗联合治疗。使用成像技术对新治疗方案的治疗效果进行无创和及时的评估将指导递送系统和治疗方案的优化，以实现最佳可能的结果并治愈疾病。本项目的具体目标是：1）首次建立图像引导的靶向多功能siRNA递送系统无创性抑制EMT治疗转移性乳腺癌的分子成像技术; 2）评估和优化图像引导的EMT调控基因沉默和靶向多功能siRNA递送系统抑制BC EMT和转移; 3）评价和优化多功能siRNA递送系统与化疗药物在治疗TNBC中的图像引导联合治疗。已经获得了大量的初步数据来证明所提出的图像引导治疗方案在治疗转移性乳腺癌中的有效性。我们的长期目标是开发一种图像引导的治疗方法，以有效治疗危及生命的转移性BC。